JMP Securities Reiterates Market Outperform Rating for ABIVAX Société Anonyme (NASDAQ:ABVX)

ABIVAX Société Anonyme (NASDAQ:ABVX)‘s stock had its “market outperform” rating reaffirmed by equities research analysts at JMP Securities in a note issued to investors on Friday,Benzinga reports. They currently have a $33.00 price target on the stock. JMP Securities’ target price indicates a potential upside of 417.24% from the stock’s previous close.

Separately, Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, ABIVAX Société Anonyme currently has a consensus rating of “Buy” and a consensus price target of $38.67.

ABIVAX Société Anonyme Trading Down 4.5 %

ABVX stock opened at $6.38 on Friday. The stock has a 50-day moving average price of $8.38 and a two-hundred day moving average price of $10.44. ABIVAX Société Anonyme has a 1 year low of $6.26 and a 1 year high of $17.02.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Several hedge funds have recently modified their holdings of ABVX. GAMMA Investing LLC bought a new position in ABIVAX Société Anonyme during the fourth quarter worth about $29,000. BNP Paribas Financial Markets grew its holdings in ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after purchasing an additional 5,900 shares during the period. Walleye Capital LLC grew its holdings in ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after purchasing an additional 80,807 shares during the period. abrdn plc grew its holdings in ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after purchasing an additional 198,225 shares during the period. Finally, Point72 Asset Management L.P. grew its holdings in ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after purchasing an additional 119,300 shares during the period. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.